Tourmaline shifts focus to developing anti-IL6 antibody following merger
Pharmaceutical Technology
OCTOBER 20, 2023
The company plans to initiate the Phase II trial of anti-IL-6 antibody in atherosclerotic cardiovascular disease in 2024.
iTeos and GSK hit enrolment milestone with Phase III TIGIT lung cancer trialĀ
Pharmaceutical Technology
JULY 9, 2024
iTeos will receive $35m from GSK as the first patient is dosed in the Phase III trial of the jointly developed monoclonal antibody EOS-448.
Trials 
130
130 Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trial to test monoclonal antibody for virus of growing concern
Drug Discovery World
JULY 2, 2024
The National Institutes of Health (NIH) is sponsoring a clinical trial to evaluate the safety of an investigational monoclonal antibody to treat enterovirus D68 (EV-D68), which can cause severe respiratory and neurological diseases such as acute flaccid myelitis (AFM). Credit: NIAID and CDC.
Antibody 59
59 
US FDA approves Eisai-Biogenās antibody for Alzheimerās
Pharmaceutical Technology
JANUARY 9, 2023
Eisai and Biogen have received approval for their antibody Leqembi (lecanemab-irmb) , 100mg/mL injection for intravenous use, from the US Food and Drug Administration (FDA) under the Accelerated Approval Pathway to treat Alzheimerās disease (AD). The regulatory approval is based on the data obtained from the Phase II trial.
FDA Approval 246
246 
Machine learning: A useful tool in the development of next generation antibody therapeutics
Drug Discovery World
MAY 21, 2024
Ben Holland , CTO and Co-Founder of Antiverse discusses how artificial intelligence and machine learning are benefitting antibody discovery and design. Modern experimental procedures, such as immunisation, B-cell screening, and synthetic library generation, have been pivotal in developing approximately 80 FDA-approved antibody therapeutics.
Antibody 59
59 
SciRhom raises ā¬63M in series A to develop antibodies against autoimmune diseases
BioPharma Reporter
JULY 11, 2024
The fundraising will support the development of SciRhomĆ¢s lead development program toward a proof-of-concept clinical trial.
Development 77
77 
AstraZeneca to deliver Covid-19 antibody therapy doses to Switzerland
Pharmaceutical Technology
JULY 21, 2022
AstraZeneca has signed a deal with the Federal Office of Public Health (FOPH) of Switzerland to deliver over 1,200 doses of antibody therapy, tixagevimab and cilgavimab combination (AZD7442), for Covid-19 prevention and treatment. In May, the company supplied the first doses of the antibody therapy to Swiss hospitals for Covid-19 prevention.
Antibody 264
264 
Eisai signs agreement with Bliss Biopharmaceutical to develop BB-1701
Pharmaceutical Technology
MAY 8, 2023
Ei s ai and Bliss Biopharmaceutical have entered into a joint development agreement for antibody-drug conjugate (ADC), BB-1701, to treat cancers. The collaboration will help in further development of BB-1701 across the world and advance the ADC towards late stage of development.
Development 246
246 
TORL BioTherapeutics raises funds to develop new oncology therapies
Pharmaceutical Technology
APRIL 14, 2023
Clinical-stage biopharmaceutical company TORL BioTherapeutics has raised $158m in a Series B financing round for advancing the development of new biologics for cancer treatment. TORL BioTherapeutics is a newly formed, US-based company focused on the development of novel antibody-based therapeutics for cancer patients.
Development 264
264 
FDA rejects Regeneron lymphoma drug, setting back companyās oncology push
Bio Pharma Dive
MARCH 25, 2024
The agency wants Regeneron to make more progress with a confirmatory trial before clearing odronextamab, a “bispecific” antibody being developed for multiple blood cancers.
Antibody 286
286 
SciRhom raises ā¬63M in series A to develop antibodies against autoimmune diseases
BioPharma Reporter
JULY 11, 2024
The fundraising will support the development of SciRhomĆ¢s lead development program toward a proof-of-concept clinical trial.
Development 52
52 
Monoclonal antibodies challenge marketed small-molecule Alzheimerās dominance
Pharmaceutical Technology
DECEMBER 6, 2022
The three leading Alzheimerās disease (AD) drugs currently in development are all monoclonal antibodiesādonanemab by Eli Lilly , lecanemab by Eisai and Biogen , and gantenerumab by Roche. Monoclonal antibodies make up half of these, with an 11% share of all AD approvals.
Antibody 147
147 
Humanised bispecific antibody for asthma enters Phase I trial
Drug Discovery World
MARCH 8, 2024
Biopharmaceutical company Innovent Biologics has launched the first-in-human (FIH) Phase I clinical trial of IBI3002, a novel bispecific antibody targeting Interleukin 4 receptor Ī± (IL-4RĪ±) and thymic stromal lymphopoietin (TSLP). In vitro assays have shown superiority over the marketed monoclonal antibodies to respective target.
Antibody 52
52 
Which diseases are poised to benefit from therapeutic antibody development
Drug Discovery World
NOVEMBER 14, 2023
DDWās Megan Thomas looks at how different diseases will benefit from the success of therapeutic antibodies. Cancer Monoclonal antibodies (mAbs) are a type of targeted drug therapy, and as such are often used to treat cancer. This is not only made clear by the fact that the global cancer mAbs market size was valued at $55.6
Antibody 59
59 
Epsilogen completes first-ever IgE antibody clinical trial
BioPharma Reporter
AUGUST 1, 2023
Epsilogen, a leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, has published phase 1 data from the first ever clinical trial of an IgE antibody therapeutic in Nature Communications.
Janssenās antibody drug shows phase 2 potential in rheumatoid arthritis
BioPharma Reporter
NOVEMBER 9, 2023
The proof-of-concept trial, dubbed IRIS-RA, is the first to investigate a treatment for rheumatoid arthritis that blocks a protein called neonatal Fc receptor (FcRn).
Antibody 105
105 
Accelerated development for Covid-19 monoclonal antibody
Drug Discovery World
JANUARY 3, 2023
A monoclonal antibody to prevent Covid-19 in vulnerable patients, AZD3152, has entered clinical trials less than 12 months after discovery. . The commencement of the trial triggers a $5 million milestone payment to RQ Bio and will enable the company to execute its four scientific programmes focused on viral diseases. .
Antibody 52
52 
Antibody for gastric cancer progresses to Phase III trials
Drug Discovery World
OCTOBER 12, 2023
The US Food and Drug Administration (FDA) has granted clearance to Transcenta to proceed with its TranStar 301 global Phase III pivotal trial of Osemitamab (TST001) for gastric cancer. The trial will investigate the drug in combination with Nivolumab and chemotherapy as a first-line treatment in patients with HER2-negative, CLDN18.2
Antibody 52
52 
Cancer Research UK and UCB advance oncology antibody candidates
Drug Discovery World
MARCH 10, 2023
Cancer Research UK and UCB have agreed a clinical development collaboration to advance two of UCBās investigational oncology antibody candidates through clinical trials. If successful in clinical trials the investigational candidates may have the potential to offer cancer patients access to new targeted treatment options.
Antibody 98
98 
Corbus and CSPC Megalith sign licence agreement for antibody drug conjugate
Pharmaceutical Technology
FEBRUARY 14, 2023
Precision oncology firm Corbus Pharmaceuticals and CSPC Megalith Biopharmaceutical have entered an exclusive licensing agreement for the latterās new clinical stage antibody drug conjugate (ADC), CRB-701 (SYS6002). We look forward to working with CSPC to advance clinical development of this asset and realise its full potential.ā
Antibody 130
130 
Umoja and IASO partner to develop therapies for haematological malignancies
Pharmaceutical Technology
NOVEMBER 22, 2022
Umoja Biopharma has signed a research agreement with IASO Biotherapeutics (IASO Bio) to develop off-the-shelf therapies for haematological malignancies. The post Umoja and IASO partner to develop therapies for haematological malignancies appeared first on Pharmaceutical Technology.
Development 276
276 
A personal view on antibody drug development
Drug Discovery World
APRIL 14, 2023
Oliver Schon, PhD, is VP Research & Development at BiVictriX Therapeutics, a UK-based emerging drug discovery and development company generating a pioneering first-in-class next-generation ADC anti-cancer therapeutics which exhibit superior selectivity towards cancer.
Antibody 52
52 
Therapeutic antibody potential in 2024
Drug Discovery World
MAY 1, 2024
DDWās Megan Thomas speaks to industry experts and thought leaders about the potential for therapeutic antibodies in 2024. Many of the best-selling drugs in 2023 were monoclonal antibody (mAB) therapies, including Keytruda (pembrolizumab), Humira (adalimumab), and Dupixent (dupilumab) 1.
Antibody 59
59 
Antibody treatment for geographic atrophy enters clinical trials
Drug Discovery World
OCTOBER 11, 2023
Collaborators Boehringer Ingelheim and CDR-Life have commenced a Phase I evaluation of BI 771716, their antibody fragment-based treatment developed to preserve the vision of people with geographic atrophy (GA). The companyās first therapeutic candidate, CDR404, targets MAGE-A4 and is expected to enter the clinic in 2024.
Astellas to support development of Tayshaās gene therapy programmes
Pharmaceutical Technology
OCTOBER 25, 2022
Ast ellas Pharma has announced plans to make a strategic investment to back the development of Taysha Gene Therapiesā adeno-associated virus (AAV) development programmes for Rett syndrome and giant axonal neuropathy (GAN). This would allow the companies to boost the development of new therapy options for Rett syndrome and GAN patients.
Gene Therapy 264
264 
95% response to bispecific antibody in follicular lymphoma
Drug Discovery World
JUNE 3, 2024
Previously untreated follicular lymphoma (FL) patients who received epcoritamab with rituximab-lenalidomide (R2) had a 95% overall response rate (ORR), according to preliminary trial data. It is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T-cell-mediated killing of CD20+ cells.
Antibody 59
59 
New inhaled SARS-CoV-2 antibody treatment set to enter clinical trials
BioPharma Reporter
DECEMBER 13, 2021
Memo Therapeutics AG will receive CHF 10.5m (US $11.4m) from the Swiss government to clinically develop a SARS-CoV-2 antibody against COVID-19, allowing it to start Phase 1 studies in Q1, 2022.
Antibody 143
143 
2024 predictions: Experts comment on monoclonal antibodiesĀ
Drug Discovery World
MARCH 12, 2024
Here, experts weigh in on the future of monoclonal antibodies (mAbs). Amanda Halford, President Bioprocess, Cytiva āIn 2024, the emphasis will remain on novel mAbs, specifically antibody drug conjugates. Innovations include next-generation antibodies with improved efficacy and reduced side effects.
Antibody 81
81 
Maxion scoops Ā£2m UK grant to develop autoimmune disease treatment
Pharmaceutical Technology
APRIL 20, 2023
The funds will support Maxionās KnotBody platform to develop antibodies to treat autoimmune diseases. Antibody-based therapies provide enhanced efficacy and safety whilst reducing the need for frequent administration for autoimmune disease treatment.
Development 130
130 
US FDA grants fast track designation for Jasperās antibody to treat SCID
Pharmaceutical Technology
SEPTEMBER 16, 2022
The US Food and Drug Administration (FDA) has granted fast track designation to Jasper Therapeuticsā antibody, JSP191, for the treatment of severe combined immunodeficiency (SCID) patients who undergo allogeneic hematopoietic stem cell transplant. . The antibody was also analysed in a total of more than 110 healthy subjects and patients. .
Antibody 130
130 
Genmabās Silver Anniversary: Reflecting on 25 Years of Breakthroughs in Antibody Therapeutics
XTalks
MAY 9, 2024
Genmab, a trailblazer in the field of antibody therapeutics, celebrates this milestone by reflecting on its impressive journey from a small-scale startup to a global leader in cancer treatment and beyond. Since then, innovative science has been at Genmabās core, as we harness the power of human antibodies to improve the lives of patients.
Antibody 52
52 
First patient dosed in trial of antibody for kidney disease
Drug Discovery World
JULY 6, 2023
The first patient has been dosed in the clinical Phase I evaluation of the Sema3A monoclonal antibody, part of the Evotec-Bayer multi-target research collaboration in kidney diseases. Sema3A is upregulated in injured human kidneys and implicated in the development and progression of acute and chronic kidney diseases.
Antibody 52
52 
How Can You Manage the Complexity of Early Phase Clinical Development?
XTalks
JUNE 4, 2024
In the ever-evolving landscape of pharmaceutical development, the complexity of early phase clinical trials is increasing. This surge in complexity is driven by escalating drug development costs, heightened competition and advanced scientific innovations. And that has a lot of downstream consequences.ā This trend, which Dr.
Three trends in the antibody-drug conjugate (ADC) marketĀ
Drug Discovery World
JUNE 1, 2023
Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. According to NCBI, most of the ADCs developed so far are for use in the treatment of cancer, but there is plenty of potential for using ADCs to treat other diseases 1.
Antibody 98
98 
Alentis Therapeutics raises funds to develop medicines for CLAUDIN-1
Pharmaceutical Technology
APRIL 13, 2023
Alentis Therapeutics intends to use the funding for the Phase II and Phase I programmes of its lead investigational products ALE.F02 and ALE.C04, first-in-class anti-Claudin-1 (CLDN1) antibodies, respectively. With a silenced effector function, ALE.F02 has been designed for targeting the stiff ECM of fibrotic tissues and organs.
Medicine 130
130 
Tiziana develops intranasal antibody for type 1 diabetes
Drug Discovery World
APRIL 27, 2023
Biotechnology company Tiziana Life Sciences is initiating a programme to develop intranasal foralumab for the treatment or prevention of type 1 diabetes. We believed that having a fully human CD3 antibody may offer benefits to patients across many different chronic disease indications.ā
Antibody 52
52 
Regeneronās antibody cocktail cuts COVID hospitalisation in large trial
pharmaphorum
MARCH 26, 2021
Regeneron has posted findings from a large trial of its COVID-19 antibody cocktail showing the therapy reduced risk of hospitalisation or death by 70%. Data from the phase 3 trial will also be used to convert an Emergence Use Authorisation into a permanent licence, Regeneron said.
Antibody 98
98 
Therini Bio raises funds to develop neurodegenerative disease therapies
Pharmaceutical Technology
APRIL 28, 2023
Biotechnology company Therini Bio has raised $36m in a Series A financing round to develop fibrin-targeted therapies to treat neurodegenerative and retinal diseases. Therini Bio will use part of the funds to advance its potential first-in-class investigational antibody, THN391, into clinical trials.
Development 130
130 
Phase I trial of lead antibody candidate launched
Drug Discovery World
NOVEMBER 15, 2022
DynamiCure has dosed the first patients in its Phase I clinical trial evaluating the first of the companyās two anti-CD93 monoclonal antibody candidates, DCBY02, in adults with a wide range of advanced cancers. . The post Phase I trial of lead antibody candidate launched appeared first on Drug Discovery World (DDW).
Antibody 52
52 
Regeneron tests COVID-19 antibody therapy in UKās RECOVERY trial
pharmaphorum
SEPTEMBER 16, 2020
Regeneronās COVID-19 antibody cocktail has been added to the UKās RECOVERY trial, one of the largest of its kind in the world that is testing several potential coronavirus therapies at the same time. REGN-COV2 is a combination of two monoclonal antibodies, designed to block infections of SARS-CoV-2, the virus that causes COVID-19.
Antibody 98
98 
Adcentrx raises funds to advance ADCs into clinical development
Pharmaceutical Technology
APRIL 26, 2023
Biotechnology company Adcentrx Therapeutics has raised $38m in Series A+ financing to advance its pipeline of new antibody-drug conjugate (ADC) therapeutics into clinical development. Adcentrx Therapeutics is focused on developing protein conjugate therapeutics to treat cancer and other life-threatening diseases.
Innovative Nipocalimab Trial for HDFN Treatment Powered by BillionToOne
XTalks
DECEMBER 28, 2023
BillionToOne, a company specializing in molecular diagnostics, has partnered with Janssen Research & Development, LLC, a Johnson & Johnson division, to conduct the AZALEA Phase III clinical trial globally. The trial is set to occur across the US, the European Union (EU) and selected global locations.
Trials 97
97 
New class of antibody cancer drug shows promise
Drug Discovery World
JULY 26, 2023
A Cancer Research UK-funded clinical trial has shown, for the first time, that a new class of antibody could benefit cancer patients whose existing treatments have stopped working. The drug, MOv18 IgE, was developed by researchers at Kingās College London.
Antibody 52
52 
Merck Enters into a Development Agreement with Daiichi for Antibody Drug Conjugates
Roots Analysis
OCTOBER 25, 2023
On 23 October 2023, Merck announced a development agreement for Daiichi Sankyoās clinical-phase antibody-drug conjugate, namely patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd), and raludotatug deruxtecan (R-DXd), targeting cancer. Merck has invested $5.5
Antibody 40
40 
Let's personalize your content